Gritstone Oncology (GRTS) Coverage Initiated by Analysts at Raymond James
Raymond James started coverage on shares of Gritstone Oncology (NASDAQ:GRTS) in a research report report published on Thursday morning, The Fly reports. The firm issued an outperform rating on the stock.
Other analysts also recently issued reports about the stock. HC Wainwright started coverage on shares of Gritstone Oncology in a report on Thursday, March 7th. They issued a buy rating and a $17.00 target price on the stock. BTIG Research boosted their target price on shares of Gritstone Oncology to $31.00 and gave the stock a buy rating in a report on Tuesday, December 11th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The company currently has an average rating of Buy and a consensus price target of $22.75.
NASDAQ GRTS opened at $10.22 on Thursday. Gritstone Oncology has a 12 month low of $9.66 and a 12 month high of $32.90.
About Gritstone Oncology
Gritstone Oncology Inc is engaged in the discovery and development of cancer immunotherapies. The company focuses on developing tumor-specific neo-antigens-based therapies for non-small cell lung cancer. Gritstone Oncology Inc has a strategic collaboration with bluebird bio, Inc The company was incorporated in 2015 and is based in San Francisco, California with operations in Cambridge, Massachusetts.
See Also: Quiet Period Expirations
Receive News & Ratings for Gritstone Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gritstone Oncology and related companies with MarketBeat.com's FREE daily email newsletter.